Twitter

Kalqyl in updated analysis of Chordate Medical after Q2: “A step closer to fulfilling the market plan”

Kalqyl has published an updated analysis of Chordate Medical following the company’s Q2 report, which was released on August 30. In the analysis, Kalqyl comments on Switzerland as a new focus market and Chordate’s sales growth of 51.8 percent during the first six months of the year. Kalqyl’s valuation of the company remains unchanged.

“The slower growth rate in Q2 was not dramatic as the business operations are still fluctuating. Furthermore, the addition of Switzerland as a focus market was positive news that positions the company one step closer to fulfilling the market plan. Overall, we believe the investment case remains intact, and our valuation remains unchanged. Looking ahead, we focus on the events surrounding the redemption of TO8 in November, which could provide the company with the necessary working capital to continue achieving the results required for the final step in the strategic plan,” writes Kalqyl in the analysis.

Read the full analysis (in Swedish)

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter